Clinical trial · Interventional
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are: * How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan? * How does the distribution of the dose to organs at risk by a radiotherapy plan based on advanced MRI compare to the distribution by the clinical radiotherapy plan? Participants will undergo an extended MRI-protocol prior to radiotherapy. This extended MRI-protocol includes the clinical brain tumor imaging protocol plus additional advanced MRI-sequences. Radiation treatment and patient follow-up will occur according to the clinical standard.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Extended or additional MRI-scan (with contrast) prior to radiotherapy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Extended MRI group
- description
- In this group, patients with a glioblastoma undergo an extended MRI-scan prior to radiotherapy.
- interventionNames
- Diagnostic Test: Extended or additional MRI-scan (with contrast) prior to radiotherapy
Primary outcomes (1)
- measure
- Pattern-of-failure analysis
- timeFrame
- The time frame is until tumor recurrence occurs (follow-up for this study will last 2 years maximum for a participant).
- description
- The primary outcome measure is a comparison of the pattern-of-failure by the radiotherapy plan based on CTVbio and the clinical radiotherapy plan (1.5-cm CTV). For both the clinical radiotherapy plan and the aMRI radiotherapy plan of each patient, the recurrence volumes will be classified as in-field, marginal, or distant recurrence if more than 80%, 20-80%, or less than 20% of the recurrence volume falls within the 95% isodose line, respectively.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent; * Adult (18 years or older); * Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy). Exclusion Criteria: * Contraindication for (3 Tesla) MRI; * Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy); * Referred for treatment of recurrent glioblastoma; * Previous radiotherapy to the brain; * Unable to give informed consent
References
Publications (0)
Data not yet available